Response rates
. | VD, % . | vtD, % . | P* . |
---|---|---|---|
After 2 cycles† | |||
CR (negative immunofixation) | 6 | 4 | .52 |
≥ nCR | 16 | 16 | 1 |
≥ VGPR | 21 | 24 | .60 |
≥ PR | 77 | 90 | .01 |
After 4 cycles‡ | |||
CR (negative immunofixation) | 12 | 13 | .74 |
≥ nCR | 22 | 31 | .15 |
≥ VGPR | 36 | 49 | .05 |
≥ PR | 81 | 88 | .19 |
After 1 course of melphalan 200 and ASCT§ | |||
CR (negative immunofixation) | 31 | 29 | .77 |
≥ nCR | 52 | 61 | .20 |
≥ VGPR | 58 | 74 | .02 |
≥ PR | 86 | 89 | .54 |
. | VD, % . | vtD, % . | P* . |
---|---|---|---|
After 2 cycles† | |||
CR (negative immunofixation) | 6 | 4 | .52 |
≥ nCR | 16 | 16 | 1 |
≥ VGPR | 21 | 24 | .60 |
≥ PR | 77 | 90 | .01 |
After 4 cycles‡ | |||
CR (negative immunofixation) | 12 | 13 | .74 |
≥ nCR | 22 | 31 | .15 |
≥ VGPR | 36 | 49 | .05 |
≥ PR | 81 | 88 | .19 |
After 1 course of melphalan 200 and ASCT§ | |||
CR (negative immunofixation) | 31 | 29 | .77 |
≥ nCR | 52 | 61 | .20 |
≥ VGPR | 58 | 74 | .02 |
≥ PR | 86 | 89 | .54 |
χ2 test.
Five and 3 patients had local and not centralized evaluations in the VD and vtD arms, respectively.
Two and 2 patients had local and not centralized evaluations in the VD and vtD arms, respectively.
Eight and 2 patients had local and not centralized evaluations in the VD and vtD arms, respectively.